The Recce Pharmaceuticals Ltd (ASX: RCE) share price is falling after the company released an update on its clinical pipeline. In afternoon trade, shares in Recce Pharmaceuticals are trading 0.46% lower at $1.08.

The update announced delays to the company’s overseas COVID-19 animal studies.

Let’s take a closer at today’s news.

Recce’s clinical pipeline update

COVID-19 studies

According to Recce, overseas studies testing the efficacy of its RECCE 529 on animals infected with COVID-19 variants has been delayed.

RECCE 529 is a synthetic anti-infective which has, to date, been studied as a treatment for COVID-19.

Some of the studies testing the ability of RECCE 529 to treat COVID-19 variants are experiencing delays, as labs struggle to infect ferrets with the variants.

Despite this, the company believes it will have data on the effectiveness of RECCE 529 against the UK and South African COVID-19 strains by the fourth quarter of 2021.

Meanwhile, Reece’s other synthetic anti-infective which has proven to be promising against COVID-19, R327, has shown more encouraging results. It has moved to the second stage of its Australian study, with results due late this year.

Burns trial

Also underway is a human clinical trial using R327 to treat burns. The eight-month trial is being conducted at Fiona Stanley Hospital in Perth, Western Australia.

Recce expects data from the burns trial to be available in the fourth quarter of 2021.

Intravenous trial

R327 is also being injected intravenously in the first phase of a human clinical trial.

According to Recce, so far, injecting R327 intravenously has been found effective in treating sepsis, kidney infections, and urinary tract infections.

The first trial will see healthy patients dosed with R327 in August 2021. Recce expects interim data from the intravenous trial late this year. Full results are likely to be available mid-2022.

Helicobacter pylori pre-clinical studies

Finally, Recce Pharmaceuticals updated the market on its oral compound (RECCE 435) designed to fight helicobacter pylori infections.

The company is currently testing RECCE 435 on mice, and expects results from the pre-clinical study in mid-2022. Recce hopes the results will lead to a clinical study next year.

Recce share price snapshot

The Recce Pharmaceuticals share price has been bobbing along on the ASX so far this year. The most notable peaks were $1.26 and $1.19 in mid-April and early May respectively.

Currently, the Recce Pharmaceuticals share price is up by around 3% year to date. It has gained 32% since this time last year.

The company has a market capitalisation of around $185 million, with approximately 173 million shares outstanding.

The post Recce (ASX:RCE) share price edges lower following study delays appeared first on The Motley Fool Australia.

More reading

• Why the Recce (ASX:RCE) share price is surging 8% higher today

The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.

from The Motley Fool Australia https://ift.tt/3ghnuh5

Often the biggest risers and fallers of the S&P/ASX 200 Index (ASX: XJO) dominate investors attention on any given day. But it’s also very interesting to look at the ASX 200 shares that are dominating trading volume. These most traded ASX shares can help us understand what is moving the markets, and sentiment, on any given day.

So with that in mind, let’s take a look at the ASX 200 shares that are swapping hands with the most volume today:

3 ASX 200 shares on the move today

Cleanaway Waste Management Ltd (ASX: CWY)

Cleanaway Waste is on the move today, with 7.25 million shares traded today at the time of writing. That’s probably the result of the Cleanaway share price falling a hefty 2.92% today to $2.66 a share. Since Cleanaway is a $5.5 billion ASX 200 company, a move of this size will inevitably result in some heavy trading activity.

There’s no obvious reason why Cleanaway is falling today though since no major news or announcements have come out of the company. Perhaps investors are in the mood for some profit-taking, seeing as Cleanaway is still up more than 21% over the past 2 months.

National Australia Bank Ltd. (ASX: NAB)

NAB shares have also been thrown around today, with 8.28 million shares traded at the time of writing. This ASX 200 bank is not having an enjoyable day. NAB shares are down 2.96% to $26.70 after spending last week rising towards its 52-week high.

Unlike Cleanaway, we might know what’s going on here though. As we discussed earlier today, NAB has just revealed that it’s under investigation by AUSTRAC regarding alleged “potential serious and ongoing non-compliance” with anti-money laundering regulations. It’s no surprise that a development like that has sparked some heavy trading.

Pilbara Minerals Ltd (ASX: PLS)

Pilbara Minerals is currently the most heavily traded ASX share in the ASX 200 Index. A whopping 13.9 million shares have swapped hands today so far. The Pilbara share price has bounced around today but is still up 2.44% currently to $1.34 a share – not too far off of its 52-week high of $1.47.

Like Cleanaway, there is no major news out today that may have sparked these volumes. However, there are many investors that are interested in lithium companies like Pilbara, considering the mineral’s role in electric vehicle batteries. In fact, Pilbara shares are now up more than 24% in just the past fortnight.

The post These 3 ASX 200 shares are on the move today appeared first on The Motley Fool Australia.

More reading

• Why Flight Centre, Mesoblast, NAB, & SkyCity shares are sinking
• Do higher interest rates look more likely than ever now?
• Star (ASX:SGR) share price latest to fall on anti-money laundering investigation
• Crown (ASX:CWN) share price under pressure from AUSTRAC enforcement investigation
• ASX 200 down 0.1%: Altium rockets, NAB hit with AUSTRAC investigation

Motley Fool contributor Sebastian Bowen owns shares of National Australia Bank Limited. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.

from The Motley Fool Australia https://ift.tt/34S1Bjt

The Globe Metals & Mining Limited (ASX: GBE) share price is up a staggering 207.69% to 12.5 cents at the time of writing. Globe shares closed at just 3.9 cents last week and opened at 5 cents this morning before having a rocket lit under them.

At one point during early afternoon trade, the company’s shares had rallied by almost 368% to 16.5 cents apiece before retreating to their current level.

What is this company?

Globe Metals & Minerals is an ASX resources company focused on resource exploration and development primarily in Africa. Its flagship project is the Kanyika Niobium Project in Malawi.

Globe Metals has been an ASX-listed company since June 2016. Until late last year, the company’s share price hadn’t really done anything remarkable. Globe shares spent a few years bumping along around 1 to 2 cents per share. But things turned around in October when Globe hit 3 cents per share and 4 cents by December.

Globe Metals shares were actually in a trading halt since Friday morning. At the time, the company said shares would resume trading on 8 June at the latest, pending an announcement. Well, we got the said announcement this morning.

So what’s going on with the Globe Metals & Mining share price today?

Globe released a statement around market open this morning. In this statement, the company informed investors the Malawi Government’s Mineral Resources Committee has reviewed Globe’s mining licence application for its Kanyika Niobium Project. The recommendation is for the grant of a mining licence.

According to Globe, this recommendation is a “critical and formal step” in obtaining a full license for its project. The company “now awaits receipt of the mining licence and subsequent execution of the Development Agreement with the Government of Malawi”.

Globe also told the markets it “is of the understanding that the licence will have a mining lease term of 25 years from the date of issue consistent with the Mines Act”.

Here’s some of what Globe’s managing director, Alistair Stephens, had to say on the news:

Globe has been working diligently and cooperatively with all stakeholders for many years to achieve grant of a  mining licence for the Kanyika Niobium Project. Formal approval from the Malawi Government’s Mineral Resources Committee to grant the Mining Licence is a significant step forward for the company’s goal of becoming a niobium producer. I am particularly pleased for the Globe team who have stayed the course despite many obstacles in recent times.

Clearly, investors are over the moon about the news, given the company has more than tripled in valuation just today. At the current share price, Globe Metals & Mining has a market capitalisation of $67.5 million.

The post ASX stock of the day: Globe Metals & Mining (ASX:GBE) shares up 200% appeared first on The Motley Fool Australia.

More reading

• Clinuvel (ASX:CUV) share price lower despite positive update
• Why ASX agricultural shares are high on institutional investors’ radars
• Why the Growthpoint (ASX:GOZ) share price just smashed a 52-week record
• EML Payments (ASX:EML) share price jumps 5% on Q3 trading update
• Here’s why this ETF could be a top option for ASX investors

Motley Fool contributor Sebastian Bowen has no position in any of the stocks mentioned. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.

from The Motley Fool Australia https://ift.tt/3z5iAwl

The Clinuvel Pharmaceuticals Limited (ASX: CUV) share price is under pressure on Monday despite the release of a positive announcement.

The biopharmaceutical company’s shares are down 2.5% to $28.07 in afternoon trade.

Despite this, the Clinuvel share price is still up an impressive 23% since the start of the year.

What did Clinuvel announce?

This morning Clinuvel announced that its afamelanotide drug has been administered to a first patient diagnosed with an acute arterial ischaemic stroke (AIS).

The release explains that the patient was enrolled in a world’s first clinical trial (CUV801) after suffering an acute stroke and being admitted to a specialist neurological hospital in Australia to receive treatment.

Clinuvel advised that a total of six adult AIS patients will be evaluated in the Phase II CUV801 study, which is focusing on the safety and therapeutic potential of afamelanotide in patients who are ineligible for standard stroke therapy.

Clinuvel’s Clinical Operations Manager, Dr Pilar Bilbao, said: “The immediate aim in acute AIS treatment, is to bring back the patient’s neurological and muscular functions by improving the blood flow to the affected site of the brain. Our unambiguous aim is to develop a treatment for 70% to 80% of the stroke patients who currently have no alternative treatment.”

Why afamelanotide?

According to the release, scientific progress has demonstrated melanocortins, including afamelanotide, provide a positive effect on the central nervous system.

Afamelanotide is known to offer neuroprotection and act as a potent anti-oxidative hormone. The drug also possesses further therapeutic benefits, activating vessels, reducing fluid formation, protecting critical nerve and brain tissue, and restoring the blood brain barrier. The latter is a critical defence mechanism protecting the brain.

If successful, this could be a lucrative therapy for Clinuvel. The company notes that AIS accounts for approximately 85% of the 15 million strokes suffered worldwide each year. Despite its prevalence, treatment options are limited and in Europe, over 85% of AIS cases presenting to hospitals are not eligible for current standard of care treatment.

The post Clinuvel (ASX:CUV) share price lower despite positive update appeared first on The Motley Fool Australia.

More reading

• Why ASX agricultural shares are high on institutional investors’ radars
• Why the Growthpoint (ASX:GOZ) share price just smashed a 52-week record
• EML Payments (ASX:EML) share price jumps 5% on Q3 trading update
• Here’s why this ETF could be a top option for ASX investors
• How much is the BHP (ASX:BHP) dividend worth today?

James Mickleboro does not own any shares mentioned. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.

from The Motley Fool Australia https://ift.tt/3uV5vm1

ASX agricultural shares are increasingly drawing the attention of institutional investors.

Among other factors, the big money is being drawn by Australia’s reputation for high-quality foods, its location near huge Southeast Asian populations, and the simple fact we produce a lot more than we consume.

And it doesn’t hurt ASX agricultural shares that total production is forecast to grow 8% year-on-year to almost $66 billion, according to the Australian Bureau of Agricultural and Resource Economics and Sciences (ABARES).

With a glance at past performance, 2020 was highly profitable for much of Australia’s farmland. As the Australian Financial Review notes:

The latest Australian Farmland Index, which tracks the performance of a $1 billion basket of premium assets, found that farmland planted to annual broadacre crops such as wheat and canola or used to graze cattle and sheep delivered a nearly 30 per cent total return in 2020.

Almonds, grapes, citrus and other crops requiring more water and labour are often strong performers. But this segment underperformed in 2020, with a 4.8% total return.

What the experts are saying

Jos Boeren is Stafford Capital Partners’ head of agriculture and food investments. Speaking of Aussie farmland, Boeren said (quoted by the AFR), “We are increasingly being contacted by institutional investors who are looking to invest significant capital into farmland and timberland.”

Indeed, the number of funds seeking to invest in Aussie agriculture is rocketing. According to Colliers International’s head of agribusiness, Rawdon Briggs, “At present, there are approximately 43 food and agribusiness funds investing in all forms of agriculture compared
to only two in 2009.”

And the arrival of big money into the sector is helping increase efficiency and productive capacity in the market.

Jim McKay, Warakirri’s managing director said, “It’s one of the reasons why you are seeing a lot of interest from global pension funds in agriculture.”

2 leading ASX agricultural shares

There are a number of quality ASX agricultural shares investors can look into. For the purposes of this article, we’ll look at 2.

First up, Rural Funds Group (ASX: RFF). The company is a real estate investment trust (REIT), which holds and leases agricultural property and equipment.

Rural Funds has a market cap of $867 million and pays a dividend yield of 4.4%, unfranked. Over the past 12 months, the Rural Funds share price has gained 26%, outpacing the 20% gains posted by the All Ordinaries Index (ASX: XAO). Year-to-date, Rural Funds’ shares have been under pressure, down 3%.

Select Harvests Limited (ASX: SHV) also has a place among the leading ASX agricultural shares. The company processes and distributes a range of nuts, dried fruits, seeds, and natural health foods.

Select Harvests has a market cap of $699 million and pays a 2.2% dividend yield, fully franked. The Select Harvests share price is down 11% over the past 12 months. 2021 has been off to a stronger start for the ASX agricultural share, which is up more than 9% year-to-date.

The post Why ASX agricultural shares are high on institutional investors’ radars appeared first on The Motley Fool Australia.

More reading

• 3 reasons why Rural Funds (ASX:RFF) could be a really good ASX dividend share
• 2 growing ASX dividend shares for an income portfolio
• 2 ASX dividend shares that could be buys in June 2021
• 2 ASX dividend shares with attractive yields
• Select Harvests (ASX:SHV) share price falls on plummeting profits

The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. Bernd Struben has no position in any of the stocks mentioned. Motley Fool Australia owns shares of and has recommended RURALFUNDS STAPLED. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.

from The Motley Fool Australia https://ift.tt/3fYZEbm

The Growthpoint Properties Australia Ltd (ASX: GOZ) share price is on the rise today. At the time of writing, shares in the real estate investment trust (REIT) are trading for $3.94 – up 1.03%. Earlier in the day, Growthpoint shares were trading as high as $4.11, smashing their 52-week record. For context, the S&P/ASX 200 Index is currently down 0.16%.

The company’s price rise comes as it declared “significant valuation gains” across its property portfolio.

Let’s take a closer look at today’s announcement.

Why the Growthpoint share price is up

In a statement to the ASX, Growthpoint Properties said that 44 of its 55 properties have been reappraised and are now worth an extra $251 million, or a 7.7% increase. The REIT estimates this will add 33 cents per security in its tangible assets.

Growthpoint claims external evaluators reassessed both its industrial and office properties and found both were more valuable than previously thought. It says its industrial properties are now worth 10.9% more to $1.5 billion and its offices are worth 5.4% more to $1.94 billion. The weighted average capitalisation rate of its industrial properties fell to 5.2%.

Growthpoint stressed the valuations are subject to “finalisation and audit” and could be further changed, either positively or negatively. The new valuations also assume no material changes to market conditions before the end of the financial year. Investors, however, still seem to be keen on the REIT regardless, judging by the Growthpoint share price action today.

Management commentary

Timothy Collyer, Growthpoint Managing Director, said:

The preliminary results of Growthpoint’s external valuations indicate the largest six-month increase on a like-for-like basis in the Group’s history.

The significant uplift reflects the substantial re-rating that has occurred across the industrial sector, driven by continued strong domestic and offshore investors’ demand for industrial assets, as well as leasing success across both our office and industrial portfolios.

We remain focused on actively managing our assets to ensure we maximise the portfolio’s value for our Securityholders.

Growthpoint share price snapshot

Over the past 12 months, the Growthpoint share price has increased by 19.8%. During the COVID-19 market sell-off of March 2020, the company’s value haemorrhaged 44.8% in the space of just 19 days! Despite today’s unambiguously good news, the REIT’s securities have still not returned to their pre-pandemic prices. Growthpoint Properties has a market capitalisation of approximately $3 billion.

The post Why the Growthpoint (ASX:GOZ) share price just smashed a 52-week record appeared first on The Motley Fool Australia.

More reading

• Clinuvel (ASX:CUV) share price lower despite positive update
• Why ASX agricultural shares are high on institutional investors’ radars
• EML Payments (ASX:EML) share price jumps 5% on Q3 trading update
• Here’s why this ETF could be a top option for ASX investors
• How much is the BHP (ASX:BHP) dividend worth today?

The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.

from The Motley Fool Australia https://ift.tt/34REcOP

The EML Payments Ltd (ASX: EML) share price is surging this afternoon after providing a trading update for FY21 Q3.

At the time of writing, the payment solutions company’s shares are up 5.8% to $3.53.

What’s moving the EML Payments share price?

This afternoon the EML Payments share price has bounced off its lunchtime low of $3.34.

Today’s update marks the first peek into the company’s performance since the bombshell announcement that led to a 45.6% selloff on 19 May.

As a refresher, the Central Bank of Ireland (CBI) informed EML that it had concerns over the company’s PFS Card Services (Ireland) business in relation to Anti-Money Laundering/Counter Terrorism Financing compliance – something that’s quite relevant for several ASX-listed companies today.

Regulatory update

According to the release, EML responded to the CBI’s letter within the defined deadline. The company maintains a dialogue with the CBI and is providing responses, data, and access to EML’s teams.

However, shareholders have been left no better off as to knowing potential decisions and/or timeframes. Addressing the matter, EML Payments has established a project governance structure in Ireland. This includes a subcommittee consisting of board members, executives, and external regulatory consultants.

Furthermore, the company expects one-off legal and advisory fees to be less than $2 million in FY21. Unfortunately, there may be a delay in program launches due to regulatory events.

Third-quarter trading update

Shareholders are absorbing the company’s Q3 FY21 update, which contains the likely catalyst for this afternoon’s EML share price performance.

The company grew substantially across various metrics compared to the prior corresponding period for the 9 months to March 2021 (unaudited), including:

• Gross Debit Volume (GDV) increasing 52% to $14.9 billion
• Revenue increasing 65% to $143.5 million
• Earnings before interest tax, depreciation, and amortisation (EBITDA) increasing 62% to $43.8 million.

Further fuelling optimism, 368 deals were said to be in the pipeline, 56 of which are in the contract negotiation stage. The company estimates the GDV of its pipeline at maturity is $8.3 billion.

Lastly, EML’s acquisition of Sentenial and Nuapay is expected to reach a transaction close depending on approvals in early July to late August.

The post EML Payments (ASX:EML) share price jumps 5% on Q3 trading update appeared first on The Motley Fool Australia.

More reading

• Why the EML Payments (ASX:EML) share price sank 42% in May
• These were the worst performing ASX 200 shares in May
• Fund managers ar buying EML Payments (ASX:EML) and this ASX share
• ASX 200 flat: Costa crashes & Fisher & Paykel Healthcare tumbles
• EML Payments (ASX:EML) share price on watch after responding to ASX query

Motley Fool contributor Mitchell Lawler owns shares of EML Payments. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. owns shares of and has recommended EML Payments. The Motley Fool Australia owns shares of and has recommended EML Payments. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.

from The Motley Fool Australia https://ift.tt/3v7bBQB

There are a large number of exchange traded funds (ETFs) to choose from on the Australian share market.

One quality option for investors to consider is the BetaShares Global Cybersecurity ETF (ASX: HACK).

What is the BetaShares Global Cybersecurity ETF?

The BetaShares Global Cybersecurity ETF provides investors with access to the leading tech companies in the growing global cybersecurity sector

This sector certainly is a great place for investors to be right now, with the threat of cyber attacks on governments and businesses continuing to grow.

In fact, research by global giant Accenture reveals that ransomware events more than doubled in 2020.

It commented: “Established ransomware operators are upping their game as they continue to focus on new monetization opportunities. The Accenture Cyber Investigations and Forensic Response (CIFR) team observed a 160% year-on-year increase in ransomware events in 2020—with little signs of any slowdown in early 2021. To plan for resilience, organizations should focus on the business and operational risks presented by the threat across their unique value chain—and prioritize planning and defense efforts accordingly.”

In light of this growing threat, demand for cybersecurity services has been increasing at a rapid rate and looks set to continue doing so in the future. This should be good news for the 40 companies included in this ETF.

Which companies are included?

Among the 40 companies that you’ll be buying a slice of are both global cybersecurity giants and emerging players from a range of global locations.

These include Accenture, Cisco, Crowdstrike, Fortinet, Okta, Splunk, and VMware.

Over the last three years this group of companies have collectively smashed the market, leading to the BetaShares Global Cybersecurity ETF generating an average total return of 18.8% per annum.

This compares to a 10.2% per annum average total return by the S&P/ASX 200 Index (ASX: XJO) over the same period.

The post Here’s why this ETF could be a top option for ASX investors appeared first on The Motley Fool Australia.

More reading

• 2 ETFs that could be buys today for any ASX share portfolio
• 2 ASX tech shares that might be buys in June 2021
• Why this quality ASX ETF is back in focus today
• 2 quality tech options for ASX investors in June
• 2 strong ETFs for ASX investors

James Mickleboro does not own any shares mentioned. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. owns shares of and has recommended BETA CYBER ETF UNITS. The Motley Fool Australia owns shares of and has recommended BETA CYBER ETF UNITS. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.

from The Motley Fool Australia https://ift.tt/3ppViwW

The BHP Group Ltd (ASX: BHP) share price is having a nice start to the trading week today. BHP shares are up by 0.45%, at the time of writing, to $48.97 per share. That looks pretty good against the broader S&P/ASX 200 Index (ASX: XJO), which is rather flat so far today, having fallen by 0.11% to 7,287.7 points.

The share price puts BHP close to its all-time high of $51.82, which it reached early last month. BHP shares have been a spectacular performer for ASX 200 investors in recent years. The Big Australian is up almost 16% year to date, around 35% over the past 12 months, and more than 160% over the past 5 years.

But that doesn’t even include the hefty returns investors have also enjoyed from BHP in the form of dividends. How much have these dividends been worth? And what can ASX investors expect from BHP in terms of income today?

BHP shares – Big Huge Payouts?

BHP’s last dividend was paid out in March (on 23 March to be precise). This interim dividend came in at $1.31 per share, fully franked. Prior to that, BHP paid out a final dividend of 75.46 cents per share, also fully franked, back in September last year.

Those dividends were high by BHP’s historical standards. The two dividends paid out prior to those two were an interim dividend of 99.4 cents per share and a final dividend of $1.14 per share, also both fully franked.

So these two most recent dividends amount to a collective $2.06 per share. That would give BHP shares a trailing dividend yield of 4.21% on current pricing. With full franking considered, this grosses up to 6.01%. That’s arguably pretty solid for an ASX 200 share in this investing climate.

Where to next for BHP’s dividend?

Since both the BHP share price and its raw dividend payouts are close (or at) historical highs, many investors might be wondering what’s next for the mining giant. Well, one broker who thinks there is plenty left in the tank is investment bank Goldman Sachs.

According to CommSec, Goldman has BHP shares rated as a buy with a 12-month price target of $53.90 a share. It reckons BHP will manage to pay out US$2.52 ($3.21) in dividends by the end of FY2021 and US$2.58 ($3.34) in FY2022.

Talk about making it rain. That would imply BHP has a forward yield of 6.56% for FY2021 and 6.82% for FY2022, based on the current share price. I’m sure shareholders are hoping these forecast dividends indeed end up in bank accounts over the next year or two.

The post How much is the BHP (ASX:BHP) dividend worth today? appeared first on The Motley Fool Australia.

More reading

• This ASX share makes money for doing nothing
• ASX 200 Weekly Wrap: ASX hits 7,300 points for the first time
• When the music stops… the investment bankers stop getting paid!
• What’s with the Rio Tinto (ASX:RIO) share price today?
• Woodside (ASX:WPL) share price climbs despite damning conservation report

Motley Fool contributor Sebastian Bowen has no position in any of the stocks mentioned. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.

from The Motley Fool Australia https://ift.tt/3z8S0Cr

There are some ASX shares that might be impressive investments to consider.

Businesses that are generating underlying profit growth could be able to produce good growth over time.

These two potential ASX share investments could be good ideas:

Betashares Nasdaq 100 ETF (ASX: NDQ)

This is an exchange-traded fund (ETF) that invests in the US share market. Specifically, it invests in 100 of the biggest businesses that are listed on the NASDAQ – a US stock exchange.

It’s one of the larger ETFs on the ASX with assets of around $1.8 billion. Betashares Nasdaq 100 ETF is invested in many of the world’s biggest businesses, that happen to be in the technology sector. That includes: Apple, Microsoft, Amazon, Alphabet, Facebook, Tesla, Nvidia and PayPal.

But, the ETF is not simply a FAANG ETF (though Netflix is in there too), investors can get diversification to many other businesses in different industries such as Comcast, Cisco Systems, Intel, PepsiCo, Broadcom, T-Mobile, Texas Instruments, Costco, Qualcomm, Applied Materials, Intuit, Starbucks, Advanced Micro Devices, Intuitive Surgical, Booking, Moderna and Zoom.

Betashares Nasdaq 100 ETF has an annual management fee of 0.48%.

Many of the above businesses are leaders in their sector in the US, or indeed globally. That allows them to benefit from economies of scale, higher margins and attractive profit profiles.

Since inception in May 2015, the ETF has produced an average return per annum of 20.9%. Past performance is not an indicator of future performance though.

Accent Group Ltd (ASX: AX1)

Accent is one of the leading ASX retail shares.

It sells through a variety of different stores and brands in Australia including Platypus, Hype, The Athlete’s Foot, Trybe, Skechers, Vans, Timberland, CAT and Dr Martens.

The company is regularly adding to its portfolio, such as the recent acquisition of Glue Store, which has a focus on the youth market. Accent says that the fragmented youth apparel market provides it with a significant opportunity to grow stores and capture market share.

This acquisition gives the business the ability to leverage its retail expertise to improve the Glue merchandise offering and customer experience. The deal was at an attractive acquisition price, with a “significant” opportunity to improve profitability.

Glue has a network of 21 stores across the country, with 14 of them in NSW. Its product range includes leading domestic and global brands and growing owned vertical brands.

Accent is rapidly growing its digital sales. In the first half of FY21, online sales accounted for 22.3% of total sales. Digital sales grew by 109.6%, with orders increasing by 100% and the conversion rate improving by 31.6%. It continues to invest in its e-commerce technology offering.

It has 21 different websites across all of its brands. The ASX share has close to 600 stores, which enables it to provide an omnichannel distribution model to shoppers with a key presence in both metro and regional areas.

The business has 8 million contactable customers. Loyalty programs are going to be rolled out starting in the second half of FY21.

Accent has a goal of continuing to grow profit over the long-term and pay dividends to shareholders.

According to Commsec, the Accent share price is valued at 19x FY21’s estimated earnings, with a grossed-up dividend yield of 6.3%.

The post 2 impressive ASX shares that could be buys in June 2021 appeared first on The Motley Fool Australia.

More reading

• 2 ASX dividend shares with attractive yields for next week
• 2 quality ASX dividend shares
• 2 top ETFs to buy in June 2021
• Accent (ASX:AX1) share price rises after sticking with Glue
• 2 ASX dividend shares that could be buys in June 2021

Motley Fool contributor Tristan Harrison has no position in any of the stocks mentioned. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. owns shares of and has recommended BETANASDAQ ETF UNITS. The Motley Fool Australia owns shares of and has recommended BETANASDAQ ETF UNITS. The Motley Fool Australia has recommended Accent Group. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.

from The Motley Fool Australia https://ift.tt/3wbix00